Rocatinlimab Effective for Moderate-to-Severe Atopic Dermatitis

Full data results will be presented at future medical conferences and in peer-reviewed journals.
Lasting improvement seen for patients receiving anti-OX40 antibody rocatinlimab compared with placebo

HealthDay News — The anti-OX40 antibody rocatinlimab is effective for adults with confirmed atopic dermatitis with moderate-to-severe disease activity, according to a study published online December 9 in The Lancet.

Emma Guttman-Yassky, MD, from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues conducted a double-blind, placebo-controlled study at 65 secondary and tertiary sites in the United States, Canada, Japan, and Germany. Eligible adult patients with confirmed atopic dermatitis with moderate-to-severe disease activity were randomly assigned to receive subcutaneous rocatinlimab every 4 weeks (150 or 600mg) or every 2 weeks (300 or 600mg) or subcutaneous placebo up to week 18, followed by an 18-week active-treatment extension and 20-week follow-up. The primary end point at week 16 was percentage change from baseline in the Eczema Area and Severity Index (EASI) score.

A total of 274 patients were enrolled between October 22, 2018, and October 21, 2019, and were randomly assigned to one of the rocatinlimab groups (217 patients; 79%) or placebo (57 patients; 21%). The researchers observed significant least-squares mean percent reductions in the EASI score at week 16 in all rocatinlimab groups compared with placebo (−48.3, −49.7, −61.1, and −57.4 vs −15.0 for rocatinlimab 150mg every 4 weeks, 600mg every 4 weeks, 300mg every 2 weeks, and 600mg every 2 weeks, respectively, vs placebo).

“At week 36, all participants had been on the treatment for at least 18 weeks,” Guttman-Yassky said in a statement. “By this time, we saw that while the drug achieved the primary end points in all doses versus the placebo, it’s also a drug that improves over time, which is really unusual and unique among currently available treatment options.”

Several authors disclosed financial ties to pharmaceutical companies, including Kyowa Kirin, which manufactures rocatinlimab and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)